— Mallinckrodt plc (NYSE: MNK) reported third-quarter 2019 earnings of $2.07 per share, vs. $1.97 per share expected.
— Revenue fell 7% to $743.7 million, vs. $770.8 million expected. Acthar Gel net sales were $229.8 million, down 20.8% YoY.
— Raised fiscal year 2019 adjusted EPS guidance range to $8.50 – $8.70, from the prior estimate of $8.40 – $8.70
— MNK shares rose 2.3% immediately following the announcement.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
